Late sodium current inhibition in acquired and inherited ventricular (dys)function and arrhythmias (Q38071920)

28 August 2017

1 reference

title

Late sodium current inhibition in acquired and inherited ventricular (dys)function and arrhythmias (English)

1 reference

28 August 2017

2

Arthur A M Wilde

1 reference

28 August 2017

Carol Ann Remme

1

1 reference

28 August 2017

publication date

1 February 2013

1 reference

Cardiovascular Drugs and Therapy

28 August 2017

published in

1 reference

28 August 2017

volume

27

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

91-101

1 reference

Pathophysiology and pharmacology of the cardiac "late sodium current.".

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

The cardiac persistent sodium current: an appealing therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Sodium channel (dys)function and cardiac arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Flecainide‐Associated Bradycardia‐Dependent Torsade de Pointes: Another Potential Mechanism of Proarrhythmia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Class I/B antiarrhythmic property of ranolazine, a novel antianginal agent, in dog and human cardiac preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Effects of lignocaine and quinidine on the persistent sodium current in rat ventricular myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Comparison of the effect of class IA antiarrhythmic drugs on transmembrane potassium currents in rabbit ventricular myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Cellular electropharmacology of amiodarone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Late sodium current is a novel target for amiodarone: studies in failing human myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Electrophysiologic basis for the antiarrhythmic actions of ranolazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Rapid kinetic interactions of ranolazine with HERG K+ current

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

[Na+]i handling in the failing human heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Calcium cycling and signaling in cardiac myocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Pathophysiology of the cardiac late Na current and its potential as a drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Increased late sodium current in myocytes from a canine heart failure model and from failing human heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Late sodium current in failing heart: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Modulation of late sodium current by Ca2+, calmodulin, and CaMKII in normal and failing dog cardiomyocytes: similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Modulation of cardiac Na(+) and Ca(2+) currents by CaM and CaMKII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Late sodium current contributes to diastolic cell Ca2+ accumulation in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Role of ranolazine in angina, heart failure, arrhythmias, and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Late sodium current inhibition as a new cardioprotective approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolazine inhibits an oxidative stress-induced increase in myocyte sodium and calcium loading during simulated-demand ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolazine--treatment of ventricular tachycardia and symptomatic ventricular premature beats in ischemic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Electrophysiological changes in heart failure and their relationship to arrhythmogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Diastolic dysfunction and arrhythmias caused by overexpression of CaMKIIδ(C) can be reversed by inhibition of late Na(+) current

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolozine-induced suppression of ventricular tachycardia in a patient with nonischemic cardiomyopathy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Cardiac sodium channel overlap syndromes: different faces of SCN5A mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Sinus node dysfunction in ATX-II-induced in-vitro murine model of long QT3 syndrome and rescue effect of ranolazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6433-X

10.1007/S10557-012-6433-X

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference